
    
      This is a phase I, open-label study to assess the safety,tolerability, pharmacokinetics and
      preliminary efficacy of SH3051 capsule, a small molecule inhibitor of type I transforming
      growth factor-β(TGF-β) receptor serine/threonine kinase, in patients with advanced solid
      tumors.
    
  